<SEC-DOCUMENT>0001104659-20-104856.txt : 20200914
<SEC-HEADER>0001104659-20-104856.hdr.sgml : 20200914
<ACCEPTANCE-DATETIME>20200914164403
ACCESSION NUMBER:		0001104659-20-104856
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200910
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200914
DATE AS OF CHANGE:		20200914

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NextCure, Inc.
		CENTRAL INDEX KEY:			0001661059
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475231247
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38905
		FILM NUMBER:		201173627

	BUSINESS ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
		BUSINESS PHONE:		240-399-4900

	MAIL ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2030788-1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt"><B>FORM 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 OR 15(d)
of The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>September 10, 2020</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NextCure, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
charter)<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><B>001-38905</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><B>47-5231247</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 48%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9000 Virginia Manor Road, Suite 200</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beltsville, Maryland </B></P></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 48%; text-align: center"><B>20705</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(240) 399-4900</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s
telephone number, including area code</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="padding: 2pt; border: Black 1pt solid; width: 42%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="padding: 2pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="padding: 2pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.001 par value per share</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NXTC</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Global Select Market</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>



<P STYLE="margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 10, 2020, the Board of Directors (the &ldquo;<B>Board</B>&rdquo;)
of NextCure, Inc. (the &ldquo;<B>Company</B>&rdquo;) appointed John G. Houston, Ph.D. to the Board. Dr. Houston fills a vacancy
created by the resignation of Judith J. Li from the Board on that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Director Resignation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Li resigned from the Board as a Class I director effective
as of September 10, 2020. Ms. Li&rsquo;s resignation from the Board was not due to any disagreement with the Company on any matter
relating to the Company&rsquo;s operations, policies or practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>New Director Appointment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 10, 2020, the Board, following the recommendation
of the nominating and corporate governance committee of the Board, elected Dr. Houston to fill the vacancy on the Board created
by Ms. Li&rsquo;s resignation, to serve as a Class I member of the Board until the Company&rsquo;s 2023 annual meeting of stockholders
and until his successor is duly elected and qualified or his earlier resignation, retirement, or removal. Dr. Houston has also
been appointed as a member of the Nominating and Corporate Governance Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Houston has served as president and chief executive
officer of Arvinas, Inc. and a member of its board of directors since September 2017 and served as its president of research
development and chief scientific officer from January 2017 to September 2017. He also currently serves on the boards of
directors of privately held Oerth Bio, Cybrexa Therapeutics and BioCT. Prior to Arvinas, he spent more than 18 years at
Bristol Myers Squibb Company (&ldquo;<B>BMS</B>&rdquo;) in roles of increasing responsibility and had accountability for all
Discovery Biology disease teams, as well as various Discovery technology departments. He was the senior vice president of
Specialty Discovery and R&amp;D Site Development at BMS from September 2015 to August 2016 and previously worked in various
roles across BMS&rsquo;s Discovery Biology, Applied Biotechnology and Early Discovery Chemistry departments. Prior to joining
BMS, he worked at Glaxo Welcome Research and Development in the United Kingdom, where he served as head of the Lead Discovery Unit.
Dr. Houston obtained a B.Sc. in Medical Microbiology from Glasgow University and a Ph.D. in Microbial Biochemistry from
Heriot-Watt University, Edinburgh.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Houston will be compensated for his service on the Board
in accordance with the Company&rsquo;s Non-Employee Director Compensation Program, a copy of which is attached to this Current
Report on Form 8-K as Exhibit 10.1. Additionally, the Company entered into a customary indemnification agreement with Dr. Houston
in connection with his appointment to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><B>Item 7.01</B></TD><TD><B>Regulation FD Disclosure.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 14, 2020, the Company issued a press release announcing
Dr. Houston&rsquo;s appointment to the Board and Ms. Li&rsquo;s resignation. A copy of the press release is attached to this Current
Report on Form 8-K as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%"><B>Exhibit No.</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%"><B>Description</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tm2030788d1_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm2030788d1_ex10-1.htm" STYLE="-sec-extract: exhibit">Non-Employee Director Compensation Program.</A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tm2030788d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm2030788d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press release of NextCure, Inc. dated September 14, 2020.</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="text-transform: uppercase"><B>NEXTCURE, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;&nbsp;Date: September 14, 2020</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Steven P. Cobourn</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Steven P. Cobourn</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2030788d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEXTCURE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Non-Employee
Director Compensation PROGRAM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This NextCure, Inc.
(the &ldquo;<U>Company</U>&rdquo;) Non-Employee Director Compensation Program (this &ldquo;<U>Program</U>&rdquo;) sets forth the
arrangements for compensation for members of the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;) who are not
employees or consultants of the Company (the &ldquo;<U>Non-Employee Directors</U>&rdquo;). All compensation paid pursuant to this
Program is subject to the terms and provisions of the NextCure, Inc. 2019 Omnibus Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;),
including, but not limited to, the requirement under the Plan that all compensation paid by the Company to any Non-Employee Director
in any calendar year shall not exceed $750,000, or $1,000,000 in the calendar year in which the applicable Non-Employee Director
is elected or appointed to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cash Compensation </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-Employee Directors
shall be entitled to receive the following annual cash compensation, payable quarterly in arrears:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A $35,000 retainer for each member (non-Chair)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A $65,000 retainer for the Chair of the
Board</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A $7,500 retainer for each member of the
Audit Committee (non-Chair)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A $15,000 retainer for the Chair of the
Audit Committee </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A $5,000 retainer for each member of the
Compensation Committee (non-Chair)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A $10,000 retainer for the Chair of the
Compensation Committee</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A $4,000 retainer for each member of the
Nominating and Corporate Governance Committee (non-Chair)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An $8,000 retainer for the Chair of the
Nominating and Governance Committee</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Retainers shall be paid promptly after
the conclusion of the applicable calendar quarter, but in no event later than 30 days after the end of the applicable calendar
quarter. In the event a&nbsp;Non-Employee&nbsp;Director does not serve as a&nbsp;Non-Employee&nbsp;Director, or in the applicable
positions described above, for an entire calendar quarter, the retainer paid to such&nbsp;Non-Employee&nbsp;Director shall be prorated
for the portion of such calendar quarter actually served as a&nbsp;Non-Employee Director, or in such position, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Equity Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Non-Employee Director
shall be entitled to receive the following awards under the Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">on the date of each Annual Meeting of
the Stockholders (&ldquo;<U>Annual Meeting</U>&rdquo;), an annual stock option award that is exercisable for 14,250 shares of the
Company&rsquo;s common stock, that vests on the earlier of
one year from the grant date of the award and immediately prior to the next Annual Meeting (the &ldquo;<U>Annual Award&rdquo;)</U>;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">for a Non-Employee Director not initially
appointed or elected to the Board at an Annual Meeting, on the date of initial appointment or election to the Board, an option
award exercisable for a number of shares equivalent to the shares subject to the Annual Award granted to other directors on the
date of the prior Annual Meeting but prorated for the remaining full months until the next Annual Meeting (or, if such meeting
has not been set, until the one year anniversary of the prior Annual Meeting), that vests on the earlier of one year
from the grant date of the Annual Award and immediately prior to the next Annual Meeting; and </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">on the date of initial appointment or
election to the Board, an initial stock option award that is exercisable for 28,500 shares of the Company&rsquo;s common stock,
that vests in three equal, annual installments commencing on the grant date of the award.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vesting for all stock option awards under
this Program is subject to the Non-Employee Director&rsquo;s continued service on the Board through the applicable vesting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All stock option awards under this Program
will be non-statutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the
Plan) of the underlying common stock on the date of grant, and shall have a fixed term of 10 years (subject to earlier termination
in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than for
cause, the post termination exercise period will be 12 months from the date of termination).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The reasonable expenses
incurred by Non-Employee Directors in connection with attendance at Board or committee meetings will be reimbursed upon submission
of appropriate substantiation in accordance with the Company&rsquo;s policies and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Effectiveness</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Program, as amended,
is effective as of June 11, 2020, and may be amended at any time in the sole discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2030788d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: red"><B><IMG SRC="tm2030788d1_ex99-1img001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NextCure Announces Appointment of John
G. Houston, Ph.D., to its Board of Directors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BELTSVILLE, Md., September 14, 2020</B> &ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>NextCure,
Inc.</U></FONT> (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class
immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston, Ph.D.,
to its board of directors as of September 10, 2020. Dr. Houston has more than 30 years of experience in the pharmaceutical and
biotech industry and currently serves as president and chief executive officer of Arvinas, Inc. In addition, Judith Li has announced
that she is stepping down from the company&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;John is an important addition to our Board of Directors.
His deep expertise in discovery biology and product development will support NextCure as we work diligently to advance our ongoing
NC318 and NC410 clinical trials, as well as our preclinical programs,&rdquo; said Michael Richman, NextCure&rsquo;s president and
chief executive officer. &ldquo;We are delighted to welcome him to NextCure and look forward to benefiting from his insights, which
we believe will help us advance our goal of bringing novel immunomedicines to patients. We would like to thank Judith for her counsel
and support since our inception,&rdquo; Mr. Richman added.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to his role as president and chief executive officer
of Arvinas, Dr. Houston also currently serves on the boards of directors of Oerth Bio, Cybrexa Therapeutics and BioCT. Prior to
Arvinas, he spent more than 18 years at Bristol Myers Squibb (BMS) in roles of increasing responsibility and had accountability
for all Discovery Biology disease teams, as well as various Discovery technology departments. He was the senior vice president
of Specialty Discovery and R&amp;D Site Development at BMS and previously worked in various roles across BMS&rsquo;s Discovery
Biology, Applied Biotechnology and Early Discovery Chemistry departments. Dr. Houston was a member of the BMS senior executive
leadership team, which reviewed and approved over 200 pre-clinical candidates for progression into early development, several of
which advanced into late stage clinical trials, and toward commercialization. He was also the principal architect and driver of
the &lsquo;Leveraging Technology&rsquo; initiative at BMS, which led to an industry-leading integrated lead discovery and optimization
process. Prior to joining BMS, he worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead
Discovery Unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Houston obtained a B.Sc. in Medical Microbiology from Glasgow
University and a Ph.D. in Microbial Biochemistry from Heriot-Watt University, Edinburgh.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About NextCure, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NextCure is a clinical-stage biopharmaceutical company committed
to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through
our proprietary FIND-IO&trade; platform, we study various immune cells to discover and understand targets and structural components
of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments
to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with
cancer types not adequately addressed by available therapies. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.nextcure.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">This
press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information
available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure&rsquo;s expectations,
beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as &ldquo;may,&rdquo;
 &ldquo;will,&rdquo; &ldquo;potential,&rdquo; &ldquo;expects,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;hope,&rdquo;
 &ldquo;towards,&rdquo; &ldquo;forward,&rdquo; &ldquo;later&rdquo; and similar expressions. Examples of forward-looking statements
in this press release include, among others, statements about the benefits of Dr. Houston as a member of NextCure&rsquo;s board
of directors, progress and NextCure&rsquo;s plans, objectives and intentions with respect to the discovery and development of immunomedicines.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from
those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19
pandemic on NextCure&rsquo;s business, including NextCure&rsquo;s clinical trials, third parties on which NextCure relies and NextCure&rsquo;s
operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure&rsquo;s limited
operating history and no products approved for commercial sale; NextCure&rsquo;s history of significant losses; NextCure&rsquo;s
need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven
approach to the discovery and development of product candidates based on NextCure&rsquo;s FIND-IO platform; and dependence on key
personnel. More detailed information on these and additional factors that could affect NextCure&rsquo;s actual results are described
in NextCure&rsquo;s filings with the Securities and Exchange Commission, including NextCure&rsquo;s most recent Form 10-K and subsequent
Forms 10-Q. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of
the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations
change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Inquiries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Timothy Mayer, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NextCure, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Operating Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(240) 762-6486</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>IR@nextcure.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Inquiries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shai Biran, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MacDougall</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(781) 591-3481</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>NextCure@macbiocom.com</U></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2030788d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2030788d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  O -\# 2(  A$! Q$!_\0
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MG^/'A]I&".P16^'WQ++D"-7)VQAWVD*"5P6&0:_&7_@FR[I^VW\!;81.D_\
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#?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
